Analysts Set Expectations for NMRA Q1 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Neumora Therapeutics in a report issued on Monday, December 16th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS and Q4 2025 earnings at ($0.44) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period in the prior year, the business posted ($1.14) EPS.

A number of other brokerages have also recently commented on NMRA. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research note on Friday, November 22nd. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.40.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $10.87 on Wednesday. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -5.81 and a beta of 3.34. The company has a 50 day moving average of $11.88 and a 200-day moving average of $11.54.

Hedge Funds Weigh In On Neumora Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NMRA. Amalgamated Bank increased its position in Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after buying an additional 2,402 shares during the last quarter. Quarry LP acquired a new position in shares of Neumora Therapeutics during the 2nd quarter worth approximately $98,000. SkyOak Wealth LLC bought a new stake in Neumora Therapeutics in the 2nd quarter valued at $147,000. Principal Financial Group Inc. bought a new stake in Neumora Therapeutics in the 2nd quarter valued at $166,000. Finally, Intech Investment Management LLC acquired a new position in shares of Neumora Therapeutics in the third quarter valued at $175,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the sale, the director now owns 20,100 shares of the company’s stock, valued at approximately $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total value of $83,500.63. Following the transaction, the insider now directly owns 322,966 shares of the company’s stock, valued at $4,847,719.66. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 26.40% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.